

Requisitioning a resolution at a GSK Annual General Meeting

Shareholders wishing to requisition a resolution may find the following information helpful, but should in any event seek their own independent legal advice.





There are occasions where shareholders may wish to draw important matters to the attention of other shareholders by proposing a resolution to be put to an Annual General Meeting (AGM). This presentation sets out that procedure.

Introduction

- The procedure for requisitioning a resolution is governed by English common law and statute
- This specifies that, unless a requisition is validly received before the end of the financial year preceding the meeting, a company's costs in complying with a requisition are to be met by requisitionists
- The funds to cover such costs must be deposited with the company before a requisition can be actioned
- GSK has estimated that the cost of complying with a requisition may be as high as £200,000.



Introduction (cont.)

- GSK's Articles of Association extends the deadline prescribed by UK law from 31 December to 31 January
- This extension provides for GSK to meet its own costs in complying with a valid requisition, if the requisition is received on or before 31 January each year
- Requisitionists who lodge a requisition after 31 January, but before the UK legal deadline of 6 weeks prior to the AGM, would, however, be required to pay a deposit and to meet GSK's costs of complying with the requisition
- Requisitionists would, however, be free to include a supplementary resolution to request that GSK pays its own costs in complying with the requisition
- Shareholders wishing to requisition a resolution may find the following information helpful, but should in any event seek their own independent legal advice. A glossary of terms is set out at the end of this document.



Index

Requisitioning a resolution

Requirements	6
Eligibility	8
Procedure	10
Drafting and submission	13
Supporting statements	15
Costs	18

Supplementary Information

Contacts Glossary of terms	2
	22



Requirements: members

- To ensure there is no question of a member or indirect investor with a small shareholding requisitioning a resolution without sufficient support from other members or indirect investors, UK law sets out minimum shareholding requirements before a requisition can be made
- For a requisition involving only shareholders whose shares are registered directly in their own name (members), a requisition must be supported by the following in order to be valid, either:
 - not less than 100 members holding shares on which there has been paid up an average sum per member of not less than £100; or
 - members representing not less than 5% of the total voting rights of all the members.



Requirements: indirect investors

- For indirect investors whose shares are held via a nominee or for GSK American
 Depository Receipts (ADR) holders, a requisition must be supported by the following in
 order to be valid:
 - not less than 100 persons holding shares directly or indirectly on which there has been paid up an average sum per person of not less than £100.



Eligibility: members

- Are you part of a group of 100 or more persons together holding £10,000 in nominal value of GSK Ordinary Shares i.e. 40,000 GSK Ordinary Shares? If the answer is 'Yes' then you should be eligible to requisition a resolution, although certain procedural formalities may be required
- If the answer to the above question is 'No' then you and the persons with whom you intend to lodge the requisition might still be eligible to requisition a resolution, if together you hold at least 5% of the total shareholder voting rights in GSK Ordinary Shares i.e. approximately 205 million GSK Ordinary Shares
- If you fulfil neither of the above criteria then you are NOT eligible to requisition a resolution.

PLEASE NOTE: if your GSK shares are not registered in your own name or you hold GSK ADRs then you should refer to page 9 which explains how you should proceed.



Eligibility: indirect investors

- Are you part of a group of 100 or more persons holding £10,000 in nominal value of GSK Ordinary Shares i.e. 40,000 GSK Ordinary Shares or the equivalent thereof in ADRs?
- If the answer is 'Yes' then you should be eligible to requisition a resolution, although certain procedural formalities may be required. If the answer is 'No' then you are NOT eligible to requisition a resolution.

PLEASE NOTE: if you hold GSK ADRs then you should refer to pages 10 and 11 which explains how you should proceed. If your GSK shares are not registered in your own name then you should refer to page 12.



Procedure: ADR holders with JP Morgan Chase (JPM)

- ADR holders who hold their ADRs directly with GSK's ADR Depositary, JPM, may submit a requisition through JPM provided that the requisition is:
 - submitted by at least 100 persons with an average of £100 of paid up share capital each and authenticated by all the persons making it; and
 - accompanied by a statement from JPM or the underlying ADR holder(s) making the request setting out the basis on which ADRs are being held by them/for them.

PLEASE NOTE: any costs associated with implementing these arrangements will not be met by GSK.



Procedure: ADR holders via a broker, nominee or other institution

- ADR holders who do not hold their ADRs via JPM may submit a requisition provided that it is:
 - submitted by at least 100 persons with an average of £100 of paid up capital each and authenticated by all the persons making it; and
 - accompanied by a statement from the relevant broker, nominee or other institution through which the ADRs are held, or the underlying ADR holder(s) making the request, setting out the basis on which ADRs are being held by them/for them.

PLEASE NOTE: any costs associated with implementing these arrangements will not be met by GSK.



Procedure: holders of Ordinary Shares via a nominee

- Indirect investors holding GSK Ordinary Shares via a nominee may submit a requisition provided that the requisition is:
 - submitted by at least 100 persons with an average of £100 of paid up share capital each and authenticated by all the persons making it; and
 - accompanied by a statement from the nominee or underlying shareholder(s) making the request setting out the basis on which the GSK shares are being held by them/for them. More details about this statement are set out on pages 15 to 17.

PLEASE NOTE: any costs associated with implementing these arrangements will not be met by GSK.



Drafting and submission

- Requisitionists are strongly recommended to seek independent legal advice on the drafting of their requisition
- Please note that GSK will not meet the requisitionists' legal or other costs in preparing a requisition.



Drafting and submission (cont.)

- Points to note:
 - The requisition should be in English and in a readable form
 - It may be in hard copy or electronic form
 - The resolution being proposed should be capable of being put to a general meeting and should not be defamatory, frivolous or vexatious
 - Where it is being submitted by members the requisition should be signed by all the persons
 making it, specifying for each member their full name, registered address, account number and
 the number of GSK Ordinary Shares they hold
 - Where a requisition is being submitted by ADR holder(s) the requisition should be accompanied by a statement setting out the name and address of the registered holder(s), the number of shares/ADRs held and the basis on which the shares/ADRs are being held.



Supporting statements

- Where a requisition for a resolution is being supported by indirect investors as part of the 100 persons requirement (as set out on pages 9 and 12) the requisition must be signed by all the persons making it and be accompanied by a statement for each indirect investor which includes the following:
 - the name and address of the registered member who holds the shares on their behalf;
 - confirmation that the member is holding those shares on their behalf in the course of business;
 - details of the number of shares held on their behalf and the total amount paid up on those shares;
 - confirmation that those shares are not held by the member on behalf of anyone else or, if they
 are, that such other persons are not involved in the requisition;
 - confirmation that at least some of the shares confer voting rights; and
 - confirmation that they have the right to instruct the member on how to exercise those voting rights.



Supporting statements (cont.)

- If any of the 100 persons is a member, the requisition must also be accompanied by a statement for each such member specifying that they hold shares otherwise than on behalf of another person or that they hold shares on behalf of one or more other persons but those persons are not involved in the requisition
- The statement above should also specify for each member the total amount paid up on the shares held
- GSK may also require that the supporting statements are accompanied with such evidence of the above matters which it may reasonably require.



Supporting statements (cont.)

- These requirements also apply where indirect investors support a 100 persons requisition for the circulation of an explanatory statement (see immediately below):
 - The proposed resolution may be accompanied by an explanatory statement of not more than 1,000 (one thousand) words, which should also be signed by each of the requisitionists
 - The resolution, and where supplied an accompanying statement, will be issued on behalf of the requisitionists without giving their names
 - A specific request should be made for each requisitionist's name to be published
 - When complying with such a request, space constraints may require that a full list of these
 names be set out in an appendix to the Notice of Meeting.



Costs

- UK law specifies that the burden of a company's costs in complying with a requisition falls on the requisitionists unless a requisition is validly received before the end of the financial year preceding the AGM (31 December).
- As a result of GSK extending this deadline to 31 January, unless a requisition is validly received on or before this date, the requisitionists are required by law to deposit with GSK a sum reasonably sufficient to meet GSK's expenses in giving effect to a requisition
 - It is estimated that the cost of requisitioning a resolution could be as high as £200,000. The
 actual costs of processing a requisition and accordingly the deposit required would be
 established at the time of receipt of a requisition
 - Requisitionists are entitled to include as part of their requisition a supplementary resolution for shareholders to authorise GSK to meet the costs of complying with the requisition. GSK would reimburse the amount deposited if the supplementary resolution is approved.



Costs (cont.)

- GSK will meet its costs in complying with a requisition provided that a valid request is received by 31 January
- Requisitionists who lodge their requisition after that date will be required to deposit with
 the company sufficient funds to cover the costs in complying with the requisition and
 should consider including a supplementary resolution seeking approval for GSK to meet
 its own costs in complying with the requisition
- If any supplementary resolution is passed allowing GSK to meet its own costs in complying with the requisition, GSK will refund the deposit within 10 working days of the AGM
- Please note that requisitionists will in any event have to meet their own costs in putting forward the requisition.

PLEASE NOTE: requisitionists may submit a supplementary resolution to seek approval for GSK to meet its costs in complying with the requisition.



Supplementary Information

Contacts and glossary of terms



Supplementary Information

Contacts

If you wish to discuss any of these requirements then please contact:

Victoria Whyte

Company Secretary

GSK plc

79 New Oxford Street

London

WC1A 1DG

Tel: +44 (0)208 047 5000



Supplementary Information

Glossary of terms

- **Requisition**: a formal request to a company from one or more of its members or indirect investors to put a resolution to an AGM.
- Resolution: a proposal for members of a company to consider and decide upon.
- ADR: an American Depositary Receipt representing two GSK Ordinary shares also referred to as an American Depositary Share (ADS).
- JPM: JPM, GSK's depositary bank, which holds ADRs on behalf of investors.
- Member: a shareholder whose name appears on the Register of Members, maintained by GSK's Registrar, Computershare.
- Indirect investor: a person on whose behalf a member holds GSK Ordinary Shares.

